AG‐012986 is a pan‐CDK (cyclin‐dependent kinase) inhibitor that has in vitro and in vivo antitumor properties but was stopped in development due in part to rapid bone‐marrow‐independent white blood cell toxicity in preclinical studies and the potential for acute and delayed immunosuppression in humans. Because peripheral lymphocytes are largely nonproliferating, it was hypothesized the toxicity of AG‐012986 was due to an off‐target mechanism and not driven by the intended pharmacology. We show the toxicity mechanism in primary human immune cells is caspase driven. T‐cells treated with AG‐012986 and acutely stimulated through the T‐cell receptor exhibited decreased toxicity while still maintaining cell division inhibition. This indicated that the pharmacology of AG‐012986 functioned as expected but the toxicity had now been decoupled through activation. Induced phosphorylation of p38 and IL‐2 production was impaired with AG‐012986. Thus, AG‐012986 could cause apoptosis of T‐cells by targeting upstream kinases in the p38 Mitogen‐activated protein kinase (MAPK) pathway and impairing cellular survival. © 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:101–108 2012; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.20415